Questcor Pharmaceuticals, Inc. (Headquarters) Reports Third Quarter Financial Results

Questcor Pharmaceuticals, Inc. (QCOR) today reported financial results for the third quarter and nine months ended September 30, 2012. Net sales for the third quarter were $140.3 million, reflecting expanded physician usage of H.P. Acthar® Gel (repository corticotropin injection) in the treatment of serious, difficult-to-treat autoimmune and inflammatory disorders. Net sales in the third quarter of 2011 were $59.8 million.